Pre-Validated Systems: Fact or Fiction?

Validation is not for the faint of heart. Most professionals in regulated industries learn computerized system validation within the structure of their own organization’s quality program. Over time, some move between companies, while others support clients as consultants. One thing becomes clear very quickly: no two organizations approach validation in exactly the same way. Even with the growing adoption of cloud platforms, risk-based strategies, and stronger supplier involvement, validation teams continue to face the same recurring question. Can you really purchase a “pre-validated” system? At first glance, the idea sounds attractive, especially when vendors promote solutions as compliant or validation-ready. For business leaders, these claims may appear reassuring and convenient. However, in Life Sciences environments, validation cannot simply be packaged and transferred as a product feature. Regulatory agencies consistently emphasize that the responsibility for ensuring compliance remains with the regulated company, not the supplier [1].  

Qualification vs. Validation: A Critical Difference 

One major source of confusion is the assumption that qualification and validation are interchangeable. They are not. 

• Qualification confirms that a system meets vendor-defined specifications. 

• Validation demonstrates that the system performs as intended within the user’s specific processes and operational context. 

For example, a vendor may deliver Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) documentation. While these deliverables can be helpful, they are typically designed to apply broadly across many customers and industries. 

That creates a key limitation: vendor documentation rarely reflects the reality of your environment.  

The Long-Term Disadvantages of “Pre-Validated” Systems 

Although supplier support can reduce some initial workload, relying too heavily on a so-called pre-validated solution can introduce significant challenges over time. 

1. Validation Cannot Be Fully Transferred 

A system is not validated in isolation. Validation must confirm that the application works correctly within your organization’s: 

• Workflows 

• Data governance practices 

• Quality procedures 

• Regulatory commitments 

• Intended use 

This is why regulators expect validation to be tied directly to how the system is actually used, not simply how it was tested by a vendor [2]. 

2. Vendor Testing Is Usually Generic 

Most supplier test packages follow a standard template. They are designed to satisfy a wide customer base, not the unique needs of a pharmaceutical manufacturer, biotech company, or clinical laboratory. 

In practice, this means critical business-specific controls are often missing, such as: 

• Batch release requirements 

• Laboratory result review processes 

• Electronic signature workflows 

• Integration with existing systems 

What appears complete on paper may leave important gaps in real operations. 

3. User Requirements Are Often Overlooked 

One of the most common pitfalls is the mismatch between supplier specifications and user expectations. A vendor protocol might verify that a backup procedure exists, but validation should confirm that: 

• Backups function correctly for this system 

• Restores are effective in realistic scenarios 

• Recovery time objectives are met 

• Procedures align with company standards 

Generic scripts cannot fully demonstrate that your requirements are satisfied. 

4. The “Shortcut” Can Become More Expensive 

Pre-validation is frequently marketed as a cost-saving option. In reality, companies often end up paying twice: First for vendor documentation packages, then again for internal rework, additional testing, and remediation. 

By the time the organization supplements missing requirements and aligns deliverables with internal quality standards, the promised efficiency may disappear. 

5. Compliance Risk from Misleading Terminology 

Perhaps the greatest concern is the false confidence created by marketing language. 

Terms like “Part 11 compliant out of the box” can be dangerously misleading. Compliance depends on far more than software functionality, it also depends on governance, configuration, procedures, and ongoing control. 

Regulators continue to highlight expectations around: 

• Audit trail review 

• Access management 

• Change control 

• Data integrity 

• Lifecycle oversight 

Failure to establish these controls can lead to inspection findings and long-term regulatory exposure [3]. 

6. Cloud Platforms Add Ongoing Complexity 

In Infrastructure as a Service (IaaS), Platform as a Service (PaaS), and Software as a Service (SaaS) environments, vendors manage much of the infrastructure and release cycle. 

This introduces additional challenges, such as: 

• Frequent system updates 

• Limited visibility into supplier testing 

• Evolving configurations 

• Shared responsibility boundaries 

A system that was “validated” at implementation may drift out of compliance if lifecycle controls are not actively maintained. 

7. Validation Must Be Sustained, Not Purchased Once 

Even if supplier documentation supports initial implementation, organizations must still plan for: 

• Periodic reviews 

• Upgrades and patches 

• Business process changes 

• Inspection readiness 

• Continuous validation and maintenance 

Validation is not a one-time event; it is an ongoing responsibility. 

Are There Any Benefits at All? 

To be fair, vendor validation deliverables can turn out to be extremely useful tools, especially when they include: 

• Strong baseline specifications 

• Structured qualification protocols 

• Supplier testing evidence 

• Support for vendor qualification activities 

However, these materials should be treated as inputs not final proof of compliance.  

So, can you buy a validated system?  

You can certainly purchase supplier documentation, testing support, and structured qualification materials. However, you cannot purchase accountability or regulatory ownership. In Life Sciences environments, validation must always demonstrate that the system works correctly for its intended use within the organization’s own processes and controls. A so-called pre-validated solution may offer a helpful starting point, but it does not replace the need for user-driven validation. Over-reliance on vendor claims can create gaps that surface later during inspections, audits, or system changes. The safest approach is to prioritize transparency, strong supplier quality practices, and lifecycle control rather than marketing promises. In the long run, compliance is sustained through continuous oversight, not a one-time purchase. 

References: 

[1] U.S. Food and Drug Administration (FDA). General Principles of Software Validation; Final Guidance for Industry and FDA Staff. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-principles-software-validation 

[2] ISPE. GAMP® 5: A Risk-Based Approach to Compliant GxP Computerized Systems. https://ispe.org/publications/guidance-documents/gamp-5 

[3] European Commission. EudraLex Volume 4 – Annex 11: Computerised Systems. https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en